Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2524213 | Biomedicine & Pharmacotherapy | 2013 | 5 Pages |
Abstract
Cancer is linked to hypercoagulability, and many studies have shown that anticoagulant drugs affect tumor progression. In this study was demonstrated that the Amblyomin-X (which is a recombinant protein that exerts similarity to the Kunitz-type inhibitors and shows pro-apoptotic effects in different tumor cell lines) and heparin (a classic anticoagulant) have similar effects on cancer progression and on normalization of the hypercoagulable state. However, Amblyomin-X showed a distinct mechanism in triggering its effects in vitro, because it exerted a cytotoxic effect in cancer cells by inducing apoptosis and promoting cell cycle arrest.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Janaína Souza Ventura, Fernanda Faria, Isabel Fátima Correia Batista, Simone Michaela Simons, Daniella Gorete Lourenço Oliveira, Katia L.P. Morais, Ana Marisa Chudzinski-Tavassi,